These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 19061675)

  • 1. Pegylated interferon alpha and ribavirin therapy may induce working memory disturbances in chronic hepatitis C patients.
    Pawelczyk T; Pawelczyk A; Strzelecki D; Rabe-Jablonska J
    Gen Hosp Psychiatry; 2008; 30(6):501-8. PubMed ID: 19061675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cognitive disturbances observed in chronic hepatitis C patients during pegylated interferon alpha and ribavirin therapy].
    Pawełczyk T; Pawełczyk A; Białkowska J; Jabłkowski M; Strzelecki D; Dworniak D; Rabe-Jabłońska J
    Psychiatr Pol; 2008; 42(6):925-41. PubMed ID: 19441669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a monotherapy in early virological responders and peginterferon alpha-2a and ribavirin versus peginterferon alpha-2a, ribavirin and amantadine triple therapy in early virological nonresponders: the SMIEC II trial in naïve patients with chronic hepatitis C.
    Angelico M; Koehler-Horst B; Piccolo P; Angelico F; Gentile S; Francioso S; Tarquini P; Vecchia RD; Ponti L; Pilleri G; Barlattani A; Grieco A; Soccorsi F; Guarascio P; Demelia L; Sorbello O; Rossi Z; Forlini G; Zaru S; Bandiera F;
    Eur J Gastroenterol Hepatol; 2008 Jul; 20(7):680-7. PubMed ID: 18679072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Attention abnormalities in patients with chronic hepatitis C after pegylated interferon alpha and ribavirin treatment].
    Pawełczyk T; Białkowska J; Jabłkowski M; Pawełczyk A; Strzelecki D; Rabe-Jabłonska J; Dworniak D
    Pol Merkur Lekarski; 2008 Sep; 25(147):226-9. PubMed ID: 19112836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pegylated interferon plus ribavirin combination therapy for chronic hepatitis C with high viral load of serum hepatitis C virus RNA, genotype 1b, discontinued on attaining sustained virological response at week 16 after onset of acute pancreatitis.
    Kim SR; Imoto S; Mita K; Taniguchi M; Sasase N; Muramatsu A; Kudo M; Kitai S; El-Shamy A; Hotta H; Hayashi Y
    Digestion; 2009; 79(1):36-9. PubMed ID: 19246919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thyroid function and changes in ultrasound morphology during antiviral therapy with pegylated interferon and ribavirin in patients with chronic hepatitis C.
    Friedrich-Rust M; Theobald J; Zeuzem S; Bojunga J
    J Viral Hepat; 2009 Mar; 16(3):168-77. PubMed ID: 19175874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alopecia universalis: a rare side effect seen on chronic hepatitis C treatment with peg-IFN and ribavirin.
    Demirturk N; Aykin N; Demirdal T; Cevik F
    Eur J Dermatol; 2006; 16(5):579-80. PubMed ID: 17101483
    [No Abstract]   [Full Text] [Related]  

  • 11. [Depressive disorders and symptoms accompanying pegylated interferon alpha and ribavirin treatment of chronic hepatitis C patients].
    Pawełczyk T; Białkowska J; Jabłkowski M; Pawełczyk A; Strzelecki D; Rabe-Jabłońska J; Dworniak D
    Pol Merkur Lekarski; 2008 Jun; 24(144):516-20. PubMed ID: 18702333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.
    Tsang OT; Zee JS; Chan JM; Li RS; Kan YM; Li FT; Lo FH; Chow DA; Cheung KW; Chan KH; Yeung YW; Ng FH; Li MK; Kwan WK; Lai TS
    J Gastroenterol Hepatol; 2010 Apr; 25(4):766-71. PubMed ID: 20492332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous sarcoidosis associated with pegylated interferon alfa and ribavirin therapy in a patient with chronic hepatitis C.
    Rogers CJ; Romagosa R; Vincek V
    J Am Acad Dermatol; 2004 Apr; 50(4):649-50. PubMed ID: 15034524
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of ocular myasthenia during pegylated interferon and ribavirin treatment for chronic hepatitis C.
    Kang HM; Park MJ; Hwang JM; Kim JW; Jeong SH
    Korean J Hepatol; 2009 Jun; 15(2):209-15. PubMed ID: 19581773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual onset of type 1 diabetes mellitus and Graves' disease during treatment with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C.
    Hayashi M; Kataoka Y; Tachikawa K; Koguchi H; Tanaka H
    Diabetes Res Clin Pract; 2009 Nov; 86(2):e19-21. PubMed ID: 19744739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome of chronic hepatitis C patients who required early termination of pegylated interferon-alpha plus ribavirin combination therapy.
    Yu ML; Dai CY; Lee LP; Hsieh MY; Hou NJ; Huang JF; Lin ZY; Chen SC; Hsieh MY; Wang LY; Chang WY; Chuang WL
    Antivir Ther; 2006; 11(8):1015-9. PubMed ID: 17302371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid dysfunction in patients with chronic hepatitis C: virus- or therapy-related?
    Vezali E; Elefsiniotis I; Mihas C; Konstantinou E; Saroglou G
    J Gastroenterol Hepatol; 2009 Jun; 24(6):1024-9. PubMed ID: 19383078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peg-interferon alpha-2a versus Peg-interferon alpha-2b in nonresponders with HCV active chronic hepatitis: a pilot study.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    J Interferon Cytokine Res; 2008 Oct; 28(10):623-9. PubMed ID: 18778199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive function does not worsen during pegylated interferon and ribavirin retreatment of chronic hepatitis C.
    Fontana RJ; Bieliauskas LA; Lindsay KL; Back-Madruga C; Wright EC; Snow KK; Lok AS; Kronfol Z; Padmanabhan L;
    Hepatology; 2007 May; 45(5):1154-63. PubMed ID: 17465000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination pegylated interferon and ribavirin therapy precipitating acute renal failure and exacerbating IgA nephropathy.
    Gordon A; Menahem S; Mitchell J; Jenkins P; Dowling J; Roberts SK
    Nephrol Dial Transplant; 2004 Aug; 19(8):2155. PubMed ID: 15252182
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.